Compare AIRE & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIRE | PHIO |
|---|---|---|
| Founded | 2021 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5M | 10.1M |
| IPO Year | 2023 | 2011 |
| Metric | AIRE | PHIO |
|---|---|---|
| Price | $0.36 | $0.77 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 163.7K | 62.5K |
| Earning Date | 11-24-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.34 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,518,498.00 | N/A |
| Revenue This Year | $196.12 | N/A |
| Revenue Next Year | $79.50 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 376.42 | N/A |
| 52 Week Low | $0.16 | $0.75 |
| 52 Week High | $3.98 | $1.88 |
| Indicator | AIRE | PHIO |
|---|---|---|
| Relative Strength Index (RSI) | 24.68 | 34.99 |
| Support Level | $0.30 | N/A |
| Resistance Level | $1.62 | $1.12 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 6.94 | 16.72 |
ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are Homebuying Services and the Technology Services segment.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.